HCL-TECHNOLOGIES
21.2.2017 21:18:05 CET | Business Wire | Press release
Three winners of HCL Grant 2017 across categories of Environment, Health and Education were today announced at a ceremony held at HCL Technologies Hub, Noida. Shri Arun Jaitley, Hon’ble Union Minister of Finance and Corporate Affairs , presided over the ceremony as the Chief Guest and felicitated the winners. Each winning NGO receives a Grant of up to INR 5 crores.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170221006559/en/
At the occasion, Shri Arun Jaitley also released a compendium titled “The Fifth Estate - NGOs transforming Rural India in Environment, Health and Education ,” which is a compilation of all the finalists of the second edition of HCL Grant.
Shri Arun Jaitley, Hon’ble Union Minister of Finance and Corporate Affairs, congratulated the winners of HCL Grant 2017 and appreciated the work of HCL and the jury.
Addressing the gathering he said , “I must compliment HCL for going into the larger society, creating an independent jury, looking at areas which need support and getting the jury to select the best so that the winners can be role models for others.”
Malcolm Gladwell , an eminent author and speaker, attended the ceremony as a Special Guest and addressed the gathering comprising Board members, senior leadership and other distinguished guests from various walks of life.
The winning NGOs across three categories are:
- Environment - Foundation of Ecological Security (Gujarat)
- Health - Child in Need Institute (CINI) (West Bengal)
- Education - MelJol (Maharashtra)
Ms. Robin Abrams, Chairperson of Jury, HCL Grant, said, “HCL Grant is so much more than the fund itself. The mark of the strategic value of any grant is leverage. From the focus on governance and sustainability, sharing of best practices and how corporates and their employees can engage with NGOs – HCL Grant delivers on strategic value for the NGOs of India and for India’s Fifth Estate. It is exciting to be a part of this kind of leverage.”
HCL Grant, a CSR commitment by HCL through HCL Foundation, envisions to contribute to rural development by strengthening NGOs through deep institutional involvement and commitment. The Grant stands testimony to the fact that only strong governance structures management capabilities and reliable impact measurement systems within NGOs can help them take up and sustain high impact, complex and social transformational projects.
The winning NGOs have been selected by an eminent jury panel. Members of the panel are Ms. Robin Abrams – Former President of Palm Computing, and the longest serving Board member of HCL Technologies; Dr. Isher Judge Ahluwalia - Leading Economist and Chairperson, Board of Governors, the Indian Council for Research on International Economic Relations; Ms. Pallavi Shroff - Eminent Legal Counsel, Shardul Amarchand Mangaldas & Co.; Mr. B.S. Baswan - Former Director, Indian Institute of Public Administration; Mr. Richard Lariviere - President, Field Museum, Chicago and Former President of the University of Oregon; Dr. John E. Kelly – Senior Vice President, Cognitive Solutions and Research, IBM Corporation; and Mr. Shiv Nadar – Founder & Chairman, HCL and Shiv Nadar Foundation.
For more information please visit www.hcltech.com/HCL-Grant .
View source version on businesswire.com: http://www.businesswire.com/news/home/20170221006559/en/
Contact:
HCL Technologies
Ajay Davessar, +91 120 43828280
VP & Global
Head - Corporate Communications
Ajay.davessar@hcl.com
Link:
Social Media:
https://www.facebook.com/https://www.facebook.com/HCLTechnologies
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom